Cytosorbents Corporation
CTSO
$0.93
$0.02372.62%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 231.72% | 81.25% | -237.77% | 45.66% | 29.45% |
| Total Depreciation and Amortization | 8.80% | -4.91% | -0.75% | -4.03% | 0.81% |
| Total Amortization of Deferred Charges | 0.11% | 0.00% | 0.00% | 1,879.44% | -200.00% |
| Total Other Non-Cash Items | -143.67% | -134.04% | 418.73% | -210.47% | -26.16% |
| Change in Net Operating Assets | 423.97% | 74.45% | -219.07% | 146.13% | -65.22% |
| Cash from Operations | 56.42% | -47.94% | 4.84% | 48.66% | 0.74% |
| Capital Expenditure | -1,657.14% | 96.97% | 54.38% | -752.25% | 60.62% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -110.42% | 18.00% | 62.48% | -44.86% | -23.72% |
| Cash from Investing | -179.24% | 62.00% | 58.38% | -150.76% | 6.30% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | -600.00% |
| Issuance of Common Stock | -- | 3,993.53% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -20,650.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 92.71% | -- |
| Cash from Financing | -100.02% | 3,993.53% | 268.59% | -101.01% | 1,819.97% |
| Foreign Exchange rate Adjustments | 900.39% | 124.46% | -224.30% | 222.06% | -1,303.45% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -141.36% | 239.10% | 13.27% | -157.16% | 187.85% |